Ajay Major, Founder and President of Pager Publications and Assistant Professor of Medicine at the University of Colorado School of Medicine, shared on X:
“RW epcoritamab R/R aNHL outcomes (CUBIC Sairah Ahmed) Blood Advances:
- 157 pts, 9 centers, med age 70, 55% prior CAR
- 46% EPCORE NHL-1 ineligible
- ORR 50% (CR 32%)
- mPFS 3.5 mos, mOS 7.6 mos; 1-yr PFS/OS 29%/38%
- worse outcomes: ECOG 2+, LDH, refractory dz, trial ineligible, PD <6 mos post-CAR
- CRS 33% (G≥3 5%), ICANS 13% (G≥3 rare), ICU admit 17% Much worse outcomes and toxicities in RW setting.”
Title: Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab
Authors: Allison M. Bock, Lei Feng, Ayushi Chauhan, Lorenzo Falchi, Reid Merryman, Sonia Godbole, Swetha K. Thiruvengadam, Andrew P. Jallouk, Ajay Major, Christopher D’Angelo, Amy Ayers, Kelsey Baron, Omnia M. Farahat, Geoffrey Shouse, Alexey Danilov, Steven Bair, Matthew Lunning, Shakthi Bhaskar, Alex F. Herrera, Yazeed Sawalha, Christopher R. Flowers, Jennifer L. Crombie, Gilles Salles, Narendranath Epperla, Sairah Ahmed.
Read The Full Article.
Other articles about B-cell lymphomas on OncoDaily.